{"id":2159,"date":"2016-12-21T14:53:29","date_gmt":"2016-12-21T13:53:29","guid":{"rendered":"http:\/\/demo.octopix.be\/imbc\/en\/?post_type=case_study&p=2159"},"modified":"2025-05-21T16:42:48","modified_gmt":"2025-05-21T14:42:48","slug":"s-a-d-tek","status":"publish","type":"case_study","link":"https:\/\/www.imbc.be\/en\/case_study\/s-a-d-tek\/","title":{"rendered":"D-TEK"},"content":{"rendered":"\n
\n

D-TEK: A niche company with a strong export component<\/h2>\n\n\n\n
\n\n\n\n

Founded in 1995, D-TEK is a biotechnology company that specializes in developing and producing diagnostic kits for autoimmune diseases, which affect 7\u201315% of the world\u2019s population. As a growing niche company, D-TEK continually invests in R&D in order to ensure its competitiveness in an ever-evolving technical market.<\/span> <\/del><\/p>\n\n\n\n

\n

\u201cIMBC has a true professional ethic and respects the evolution and philosophy of our company. They support us at every crucial stage of our growth with investments and sound advice,<\/em>\u201d<\/em> Alain Vigneron, Founder and Managing Director.<\/p>\n<\/blockquote>\n\n\n\n

\n
\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n<\/figure>\n\n\n\n

In 1995, D-TEK began using an emerging technology to improve the diagnosis of autoimmune diseases. The company turned to IMBC for funding to support its R&D projects.<\/p>\n\n\n\n

\n\n\n\n

Investment for Growth<\/h2>\n\n\n\n
\n\n\n\n

2008 was a pivotal year for D-TEK. Faced with growing competition and rapid technological inflation, the company had to deal with major challenges, including expanding its teams, investing in R&D, constructing a new building, and buying back shares in a management buyout in order to retain control of the company following the departure of one of its partners.<\/p>\n\n\n\n

On each occasion, D-TEK approached IMBC with a view to working in partnership, seeking advice and coordinating a balanced financial package to create long-term value.<\/p>\n\n\n\n

D-TEK is a real case study for IMBC. For 30 years, IMBC has supported D-TEK throughout its development by financing various needs, such as R&D, investments, WCR, and MBO, both as a creditor and as a shareholder.<\/p>\n\n\n\n

\n

\u201cSince D-TEK was founded in 1995, IMBC has been a key partner in our development, providing consulting services that extend well beyond the financial realm,\u201d says Beno\u00eet Autem.<\/em><\/p>\n<\/blockquote>\n\n\n\n

\n\n\n\n

External Growth: the D-TEK Group<\/h2>\n\n\n\n
\n\n\n\n

2018 was another important year for the company, with several major projects being carried out at the same time, enabling the company to pursue both internal and external growth.<\/p>\n\n\n\n

In an effort to achieve vertical integration, D-TEK partnered with a company that assembles automation equipment for its Blue Diyer Instrument, as well as with a distributor of human and veterinary in vitro diagnostics products.<\/p>\n\n\n\n

The year was also marked by a second management buyout, in which Mr. Alain Vigneron purchased Mr. Beno\u00eet Autem\u2019s shares. Since then, the D-TEK Group has been under the leadership of Beno\u00eet Autem. Alain Vigneron, who remains with the company, has returned to his first love: R&D.<\/p>\n\n\n\n

IMBC has been there every step of the way.<\/p>\n\n\n\n

Thanks to this 30-year partnership, D-TEK has successfully navigated all of these crucial stages in its corporate life.<\/p>\n\n\n\n

\n
\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n<\/figure>\n\n\n\n
\"\"<\/figure>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Founded in 1995, D-TEK is a biotechnology company that specializes in developing and producing diagnostic kits for autoimmune diseases. As a growing niche company, D-TEK continually invests in R&D in order to ensure its competitiveness in an ever-evolving technical market.<\/p>\n","protected":false},"featured_media":2186,"menu_order":3,"template":"","format":"standard","directory_category":[246],"class_list":["post-2159","case_study","type-case_study","status-publish","format-standard","has-post-thumbnail","hentry","directory_category-chemistry-and-biotechnology"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.imbc.be\/en\/wp-json\/wp\/v2\/case_study\/2159","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.imbc.be\/en\/wp-json\/wp\/v2\/case_study"}],"about":[{"href":"https:\/\/www.imbc.be\/en\/wp-json\/wp\/v2\/types\/case_study"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.imbc.be\/en\/wp-json\/wp\/v2\/media\/2186"}],"wp:attachment":[{"href":"https:\/\/www.imbc.be\/en\/wp-json\/wp\/v2\/media?parent=2159"}],"wp:term":[{"taxonomy":"directory_category","embeddable":true,"href":"https:\/\/www.imbc.be\/en\/wp-json\/wp\/v2\/directory_category?post=2159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}